4,901 trials
Hypoparathyroidism
Primary: Baseline-adjusted Cmax of PTH(1-84) — 295.662; 330.820; 175.468; 99.708 Picogram per milliliter (pg/mL)
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants
Healthy Adults
Primary: Mean Plasma Concentration (AUC) of Cyclobenzaprine — 70066.90; 64711.53 pg*h/mL
Chronic Kidney Disease, Secondary Hyperparathyroidism
Primary: Common Treatment-emergent Adverse Events — 2; 2; 2 Participants
Healthy
Primary: Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge — 687.02; 872.61…
Musculoskeletal Diseases
Primary: ACE-083 Safety and Tolerability: Number of Subjects With Adverse Events — 6; 6; 6; 6 Participants
Healthy
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin and Gliclazide — 4974.2507; 8556.7752; 21192.1682; 21815.4021…
Retinal Degeneration · Primary Open-angle Glaucoma
Primary: Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR) — 1 Participants
Escherichia Coli Infection
Primary: Safety - Occurrence of Adverse Events — 7; 21; 19; 20 Number of Adverse Events
Major Depressive Disorder
Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Theophylline — 70200; 78700 nanogram*hour per milliliter…
Influenza
Primary: Occurrence of Solicited Injection Site and Systemic Reactogenicity on the Day of Study Product Administration Through 7 Days After Administration. — 20; 4; 21; 4 Reactions
Asthma · Chronic Obstructive Pulmonary Disease
Primary: Area Under the Concentration-time Curve From Zero to Infinity (AUCinf) — 72210; 76220 day·ng/mL
Postmenopausal · Osteopenia
Primary: Number of Participants With Adverse Events — 10; 6; 6; 6 Participants
Cardiovascular
Primary: Number of Participants With Adverse Events (AEs) — 3; 0; 0; 2 Participants